Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04973605 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
A Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 246
- Enrollment target
- 20
- Study locations
NCT04973605: Recruiting Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by BeOne Medicines.
NCT04973605 is a Phase 1 study of Relapsed/Refractory Multiple Myeloma that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 246 participants, above the 155-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (59% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04973605, a Phase 1 study of Relapsed/Refractory Multiple Myeloma, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 246 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14). The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.
Primary Outcome
DLTs will be based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 and will include most grade 3 or higher events, as defined in the protocol.
Conditions Studied
Interventions
- DRUG Sonrotoclax
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG Pomalidomide
- DRUG Carfilzomib
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- City of Hope Irvine Lennar - Irvine
- University of California At San Francisco - San Francisco
Illinois
- University of Chicago Medical Center - Chicago
- Southern Illinois University School of Medicine - Springfield
New York
- Weill Cornell Medical College Newyork Presbyterian Hospital - New York
- Memorial Sloan Kettering Cancer Center Mskcc - New York
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
- Medical College of Wisconsin - Milwaukee
Alabama
- University of Alabama At Birmingham Hospital - Birmingham
Florida
- University of Miami - Miami
Georgia
- Emory University Winship Cancer Center - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What NCT04973605 shows while recruiting
NCT04973605 is an interventional study that assigns participants to a tested intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap, above the 155-participant average among 14 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (59% higher).
The record links to 1 condition, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Sonrotoclax is the first listed.
NCT04973605 names 20 study sites across 15 states, led by California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT04973605 about?
NCT04973605 is a clinical study titled "A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma". The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14). The study investigates sonrotoclax alone and in combinatio...
What is the current status of trial NCT04973605?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 246 participants. The study started on 2021-09-16. Estimated completion is 2026-11.
What conditions does trial NCT04973605 study?
This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT04973605?
The interventions under investigation include: Sonrotoclax (DRUG), Dexamethasone (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT04973605?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04973605 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04973605's enrollment target sits among peer trials
246 5th of 14 higher than 10 of 14 other Relapsed/Refractory Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsed/Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- NCT04269902 · 247 participants · Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI